Summit Financial Wealth Advisors’s Akero Therapeutics AKRO Stock Holding History

Summit Financial Wealth Advisors’s Portfolio AKRO Stock Details AKRO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q4	–	Sell	-7,155	Closed	-$333K	–	196
2025 Q3	$333K	Hold	7,155	–	–	0.05%	128
2025 Q2	$382K	Hold	7,155	–	–	0.07%	111
2025 Q1	$290K	Hold	7,155	–	–	0.06%	118
2024 Q4	$385K	Hold	7,155	–	–	0.08%	104
2024 Q3	$205K	Buy	+7,155	New	+$187K	0.04%	145

Other funds holding AKRO

DekaBank Deutsche Girozentrale Frankfurt, Germany $59.2B AUM 26.02% 1-Year Est. Return

IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return

Summit Financial Wealth Advisors's AKRO Position: Q4 2025 in Review

Summit Financial Wealth Advisors sold out of Akero Therapeutics (AKRO) in Q4 2025, closing a stake of 7,155 shares — an estimated $333K sold.

Summit Financial Wealth Advisors first reported a position in AKRO in Q3 2024 and held it in 5 quarters. The position peaked at $385K in Q4 2024. 2 funds tracked by Wall St. Rank hold AKRO as of Q4 2025.

Summit Financial Wealth Advisors reported no remaining Akero Therapeutics position as of Q4 2025 after selling out during the quarter.
Summit Financial Wealth Advisors sold 7,155 Akero Therapeutics shares in Q4 2025, an estimated $333K.
Summit Financial Wealth Advisors first reported a position in Akero Therapeutics in Q3 2024 and held it in 5 quarters.
Summit Financial Wealth Advisors's Akero Therapeutics position peaked at $385K in Q4 2024.
2 funds tracked by Wall St. Rank held Akero Therapeutics as of Q4 2025.

Based on Summit Financial Wealth Advisors's 13F filing for Q4 2025, filed 27 Jan 2026.